Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A Class I Haemophilus ducreyi Strain Containing a Class II hgbA Allele Is Partially Attenuated in Humans: Implications for HgbA Vaccine Efficacy Trials.

Leduc I, Fortney KR, Janowicz DM, Zwickl B, Ellinger S, Katz BP, Lin H, Dong Q, Spinola SM.

Infect Immun. 2019 Jun 20;87(7). pii: e00112-19. doi: 10.1128/IAI.00112-19. Print 2019 Jul.

PMID:
31036601
2.

Typical physics Ph.D. admissions criteria limit access to underrepresented groups but fail to predict doctoral completion.

Miller CW, Zwickl BM, Posselt JR, Silvestrini RT, Hodapp T.

Sci Adv. 2019 Jan 23;5(1):eaat7550. doi: 10.1126/sciadv.aat7550. eCollection 2019 Jan.

3.

The Human Skin Microbiome Associates with the Outcome of and Is Influenced by Bacterial Infection.

van Rensburg JJ, Lin H, Gao X, Toh E, Fortney KR, Ellinger S, Zwickl B, Janowicz DM, Katz BP, Nelson DE, Dong Q, Spinola SM.

MBio. 2015 Sep 15;6(5):e01315-15. doi: 10.1128/mBio.01315-15.

4.

Phosphoethanolamine Transferase LptA in Haemophilus ducreyi Modifies Lipid A and Contributes to Human Defensin Resistance In Vitro.

Trombley MP, Post DM, Rinker SD, Reinders LM, Fortney KR, Zwickl BW, Janowicz DM, Baye FM, Katz BP, Spinola SM, Bauer ME.

PLoS One. 2015 Apr 22;10(4):e0124373. doi: 10.1371/journal.pone.0124373. eCollection 2015.

5.

Outer membrane protein P4 is not required for virulence in the human challenge model of Haemophilus ducreyi infection.

Janowicz DM, Zwickl BW, Fortney KR, Katz BP, Bauer ME.

BMC Microbiol. 2014 Jun 24;14:166. doi: 10.1186/1471-2180-14-166.

6.

A (p)ppGpp-null mutant of Haemophilus ducreyi is partially attenuated in humans due to multiple conflicting phenotypes.

Holley C, Gangaiah D, Li W, Fortney KR, Janowicz DM, Ellinger S, Zwickl B, Katz BP, Spinola SM.

Infect Immun. 2014 Aug;82(8):3492-502. doi: 10.1128/IAI.01994-14. Epub 2014 Jun 9.

7.

Haemophilus ducreyi Hfq contributes to virulence gene regulation as cells enter stationary phase.

Gangaiah D, Labandeira-Rey M, Zhang X, Fortney KR, Ellinger S, Zwickl B, Baker B, Liu Y, Janowicz DM, Katz BP, Brautigam CA, Munson RS Jr, Hansen EJ, Spinola SM.

MBio. 2014 Feb 11;5(1):e01081-13. doi: 10.1128/mBio.01081-13.

8.

Carbon storage regulator A contributes to the virulence of Haemophilus ducreyi in humans by multiple mechanisms.

Gangaiah D, Li W, Fortney KR, Janowicz DM, Ellinger S, Zwickl B, Katz BP, Spinola SM.

Infect Immun. 2013 Feb;81(2):608-17. doi: 10.1128/IAI.01239-12. Epub 2012 Dec 10.

9.

Permeases of the sap transporter are required for cathelicidin resistance and virulence of Haemophilus ducreyi in humans.

Rinker SD, Gu X, Fortney KR, Zwickl BW, Katz BP, Janowicz DM, Spinola SM, Bauer ME.

J Infect Dis. 2012 Nov;206(9):1407-14. doi: 10.1093/infdis/jis525. Epub 2012 Aug 28.

10.

Sialylation of lipooligosaccharides is dispensable for the virulence of Haemophilus ducreyi in humans.

Spinola SM, Li W, Fortney KR, Janowicz DM, Zwickl B, Katz BP, Munson RS Jr.

Infect Immun. 2012 Feb;80(2):679-87. doi: 10.1128/IAI.05826-11. Epub 2011 Dec 5.

11.

Expression of the Flp proteins by Haemophilus ducreyi is necessary for virulence in human volunteers.

Janowicz DM, Cooney SA, Walsh J, Baker B, Katz BP, Fortney KR, Zwickl BW, Ellinger S, Munson RS Jr.

BMC Microbiol. 2011 Sep 22;11:208. doi: 10.1186/1471-2180-11-208.

12.

A Haemophilus ducreyi CpxR deletion mutant is virulent in human volunteers.

Labandeira-Rey M, Dodd D, Fortney KR, Zwickl B, Katz BP, Janowicz DM, Spinola SM, Hansen EJ.

J Infect Dis. 2011 Jun 15;203(12):1859-65. doi: 10.1093/infdis/jir190.

13.

Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation of highly active antiretroviral therapy.

Knox KS, Vinton C, Hage CA, Kohli LM, Twigg HL 3rd, Klatt NR, Zwickl B, Waltz J, Goldman M, Douek DC, Brenchley JM.

J Virol. 2010 Sep;84(18):9010-8. doi: 10.1128/JVI.01138-10. Epub 2010 Jul 7.

14.

Activation of the CpxRA system by deletion of cpxA impairs the ability of Haemophilus ducreyi to infect humans.

Spinola SM, Fortney KR, Baker B, Janowicz DM, Zwickl B, Katz BP, Blick RJ, Munson RS Jr.

Infect Immun. 2010 Sep;78(9):3898-904. doi: 10.1128/IAI.00432-10. Epub 2010 Jul 6.

15.

Haemophilus ducreyi SapA contributes to cathelicidin resistance and virulence in humans.

Mount KL, Townsend CA, Rinker SD, Gu X, Fortney KR, Zwickl BW, Janowicz DM, Spinola SM, Katz BP, Bauer ME.

Infect Immun. 2010 Mar;78(3):1176-84. doi: 10.1128/IAI.01014-09. Epub 2010 Jan 19.

16.

Inactivation of the Haemophilus ducreyi luxS gene affects the virulence of this pathogen in human subjects.

Labandeira-Rey M, Janowicz DM, Blick RJ, Fortney KR, Zwickl B, Katz BP, Spinola SM, Hansen EJ.

J Infect Dis. 2009 Aug 1;200(3):409-16. doi: 10.1086/600142.

17.

A fibrinogen-binding lipoprotein contributes to the virulence of Haemophilus ducreyi in humans.

Bauer ME, Townsend CA, Doster RS, Fortney KR, Zwickl BW, Katz BP, Spinola SM, Janowicz DM.

J Infect Dis. 2009 Mar 1;199(5):684-92. doi: 10.1086/596656.

18.

Strong dispersive coupling of a high-finesse cavity to a micromechanical membrane.

Thompson JD, Zwickl BM, Jayich AM, Marquardt F, Girvin SM, Harris JG.

Nature. 2008 Mar 6;452(7183):72-5. doi: 10.1038/nature06715. Erratum in: Nature. 2008 Apr 17;452(7189):900.

PMID:
18322530
19.

Promoting adaptive coping by persons with HIV disease: evaluation of a patient/partner intervention model.

Fife BL, Scott LL, Fineberg NS, Zwickl BE.

J Assoc Nurses AIDS Care. 2008 Jan-Feb;19(1):75-84. doi: 10.1016/j.jana.2007.11.002.

20.

Renal disease in an antiretroviral-naïve HIV-infected outpatient population in Western Kenya.

Wools-Kaloustian K, Gupta SK, Muloma E, Owino-Ong'or W, Sidle J, Aubrey RW, Shen J, Kipruto K, Zwickl BE, Goldman M.

Nephrol Dial Transplant. 2007 Aug;22(8):2208-12.

PMID:
17652119
21.
22.

Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication.

Janowicz DM, Tenner-Racz K, Racz P, Humphreys TL, Schnizlein-Bick C, Fortney KR, Zwickl B, Katz BP, Campbell JJ, Ho DD, Spinola SM.

J Infect Dis. 2007 May 15;195(10):1443-51. Epub 2007 Apr 5.

23.

Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection.

Spinola SM, Bong CT, Faber AL, Fortney KR, Bennett SL, Townsend CA, Zwickl BE, Billings SD, Humphreys TL, Bauer ME, Katz BP.

Infect Immun. 2003 Nov;71(11):6658-63.

25.

Comparative evaluation of ofloxacin and metronidazole in the treatment of bacterial vaginosis.

Covino JM, Black JR, Cummings M, Zwickl B, McCormack WM.

Sex Transm Dis. 1993 Sep-Oct;20(5):262-4.

PMID:
8235922
26.

Compliance with antibiotic therapy for Chlamydia trachomatis and Neisseria gonorrhoeae.

Katz BP, Zwickl BW, Caine VA, Jones RB.

Sex Transm Dis. 1992 Nov-Dec;19(6):351-4.

PMID:
1492264
27.

Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection.

Black JR, Long JM, Zwickl BE, Ray BS, Verdon MS, Wetherby S, Hook EW 3rd, Handsfield HH.

Antimicrob Agents Chemother. 1989 Feb;33(2):167-70.

28.

Symptomatic and asymptomatic cervical infections with human papillomavirus during pregnancy.

Fife KH, Rogers RE, Zwickl BW.

J Infect Dis. 1987 Dec;156(6):904-11.

PMID:
2824625
30.

Moxalactam treatment of uncomplicated gonorrhea in women.

Jones RB, Ray BS, Zwickl BW.

Sex Transm Dis. 1984 Oct-Dec;11(4):287-90.

PMID:
6441273

Supplemental Content

Loading ...
Support Center